Table 3.
Reported frequency of buried metaplasia after photodynamic therapy for Barrett's esophagus
| Report first author | Degree of neoplasia | Number of patients | Number of biopsies | Mandated surveillance biopsy protocol | Biopsy depth | Duration of follow-up | Percent found to have buried metaplasia |
|---|---|---|---|---|---|---|---|
| Bronner et al. (15) | HGD | 138 treated 70 controls |
23,498 treated 10,160 controls |
Yes | NR | 5 Years | 30% in treatment group 33% in control group |
| Hornick et al. (20) | HGD, EC, IA | 12 | NR | No | NR | 3–38 Months | 25% |
| Schembre et al. (21) | HGD, IMC | 42 (PDT arm) | NR | Yes | NR | Median 20 months | 11.9% |
| Mino-Kenudson et al. (8) | HGD, superficial carcinoma, or IA | 52 | 1302 | Yes | NR | Mean 29.3 months | 17.3% with buried metaplasia 25% with buried neoplasia (HGD, LGD, or AC) |
| Fourolis and Thorpe (22) | HGD, IMC, or T2 AdenoCa | 31 | NR | Surveillance mandated, biopsy protocol NR | NR | Median 14 months | 20% (5 of 25 with HGD or IMC before treatment) |
| Ragunath et al. (11) | HGD, LGD | 13 | NR | Yes | NR | 12 Months | 7.7% |
| Peters et al. (23) | HGD, EC | 28 | NR | Yes | NR | Median 19 months | 25% |
| Ban et al. (10) | HGD, EC | 33 | 478 | Yes | NR | Mean 16.7 months | 51.5% |
| Etienne et al. (24) | HGD, IMC | 12 | NR | Yes | NR | Mean 34 months | 0% |
| Hage et al. (25) | No dysplasia, LGD | 24 | NR | Yes | NR | Median 12 months | 4.2% |
| Kelty et al. (26) | No dysplasia | 25 | NR | Yes | NR | 4 Weeks | 24% |
| Kelty et al. (27) | No dysplasia | 34 | NR | Yes | NR | Median 12 months | 24% |
| Wolfsen et al. (28) | HGD and IMC | 102 | NR | Yes | NR | Median 1.6 years | 4% |
| Overholt et al. (9) | LGD, HGD, EC | 102 | NR | Yes | NR | Mean 50.65 months | 3% |
| Wolfsen et al. (14) | HGD EC |
48 | NR | Yes | NR | Median 18.5 months | 2.1% |
| Buttar et al. (29) | IMC, IA | 17 | NR | Yes | NR | Mean 13 months | 0% |
| Ackroyd et al. (30) | LGD | 18 | NR | Yes | NR | 2 Years | 0% |
| Ackroyd et al. (31) | LGD | 40 | NR | Surveillance mandated, biopsy protocol NR | NR | 12 Months | 0% |
| Overholt et al. (12) | HGD or EC | 100 | NR | Yes | NR | Mean 19 months | 5% |
| Gossner et al. (32) | HGD or EC | 32 | NR | Yes | NR | NR | 6.25% |
| Barr et al. (33) | HGD | 5 | NR | “Multiple biopsies” Q 2 months | NR | 26–44 Months | 40% |
| Overholt and Panjehpour (34) | EC, HGD, LGD, No dysplasia | 45 | NR | Yes | NR | 6–66 Months | 4.4% |
EC, early cancer; HGD, high-grade dysplasia; IA, invasive adenocarcinoma; IMC, intramucosal carcinoma; LGD, low-grade dysplasia; NR, not reported.
Note: A number of reports share the same authors, and we cannot exclude the possibility that some patients were included in more than one series.